Stavudine (CAS 220020-60-0) — formula C10H12N2O4, molecular weight 224.21.
| CAS Number | 220020-60-0 |
|---|---|
| Molecular Formula | C10H12N2O4 |
| Molecular Weight | 224.21 |
| Melting Point | 318 to 320 °F (NTP, 1992) |
| LogP | -0.72 |
| Applications | Uses: Antiviral, Medication, Use (kg, approx.) in Germany (2009): >10, Use (kg) in USA (2002): 1200, Consumption (g per capita, approx.) in Germany (2009): 0.000122, Consumption (g per capita) in the USA (2002): 0.00425, Calculated removal (%): 75.1, For the treatment of human immunovirus (HIV) infections., Methods of Manufacturing: Large scale production: J.E. Starrett et al, EP 334368, eidem, US 5130421 (1989, 1992 both to Bristol-Myers), Formulations, Preparations: Zerit, Oral: Capsules: 15 mg Zerit (with parabens), (Bristol-Myers Squibb), 20 mg Zerit (with parabens), (Bristol-Myers Squibb) 30 mg Zerit (with parabens), (Bristol-Myers Squibb) 40 mg Zerit (with parabens), For solution: 1 mg, mL Zerit (with parabens), (Bristol-Myers Squibb)., General Manufacturing Information: While data specific to stavudine were not available(SRC, 2005), the literature suggests that some pharmaceutically active compounds originating from human and veterinary therapy are not eliminated completely in municipal sewage treatment plants and are therefore discharged into receiving waters(1). Wastewater treatment processes often were not designed to remove them from the effluent(2). Selected organic waste compounds may be degrading to new and more persistent compounds that may be released instead of or in addition to the parent compound(2). Studies have indicated that several polar pharmaceutically active compounds can leach through subsoils into aquifers(1). |
Documented applications: Uses: Antiviral, Medication, Use (kg, approx.) in Germany (2009): >10, Use (kg) in USA (2002): 1200, Consumption (g per capita, approx.) in Germany (2009): 0.000122, Consumption (g per capita) in the USA (2002): 0.00425, Calculated removal (%): 75.1, For the treatment of human immunovirus (HIV) infections., Methods of Manufacturing: Large scale production: J.E. Starrett et al, EP 334368, eidem, US 5130421 (1989, 1992 both to Bristol-Myers), Formulations, Preparations: Zerit, Oral: Capsules: 15 mg Zerit (with parabens), (Bristol-Myers Squibb), 20 mg Zerit (with parabens), (Bristol-Myers Squibb) 30 mg Zerit (with parabens), (Bristol-Myers Squibb) 40 mg Zerit (with parabens), For solution: 1 mg, mL Zerit (with parabens), (Bristol-Myers Squibb)., General Manufacturing Information: While data specific to stavudine were not available(SRC, 2005), the literature suggests that some pharmaceutically active compounds originating from human and veterinary therapy are not eliminated completely in municipal sewage treatment plants and are therefore discharged into receiving waters(1). Wastewater treatment processes often were not designed to remove them from the effluent(2). Selected organic waste compounds may be degrading to new and more persistent compounds that may be released instead of or in addition to the parent compound(2). Studies have indicated that several polar pharmaceutically active compounds can leach through subsoils into aquifers(1)..
Stavudine is a chemical compound with CAS registry number 220020-60-0 and molecular formula C10H12N2O4 (molecular weight 224.21).
CAS number: 220020-60-0
Its molecular formula C10H12N2O4 comprises 10 C, 12 H, 2 N, 4 O atoms.
Also known as: Stavudine
The CAS registry number of Stavudine is 220020-60-0.
Molecular formula C10H12N2O4, molecular weight 224.21.
It is also registered under: Stavudine.
Recorded applications: Uses: Antiviral, Medication, Use (kg, approx.) in Germany (2009): >10, Use (kg) in USA (2002): 1200, Consumption (g per capita, approx.) in Germany (2009): 0.000122, Consumption (g per capita) in the USA (2002): 0.00425, Calculated removal (%): 75.1, For the treatment of human immunovirus (HIV) infections., Methods of Manufacturing: Large scale production: J.E. Starrett et al, EP 334368, eidem, US 5130421 (1989, 1992 both to Bristol-Myers), Formulations, Preparations: Zerit, Oral: Capsules: 15 mg Zerit (with parabens), (Bristol-Myers Squibb), 20 mg Zerit (with parabens), (Bristol-Myers Squibb) 30 mg Zerit (with parabens), (Bristol-Myers Squibb) 40 mg Zerit (with parabens), For solution: 1 mg, mL Zerit (with parabens), (Bristol-Myers Squibb)., General Manufacturing Information: While data specific to stavudine were not available(SRC, 2005), the literature suggests that some pharmaceutically active compounds originating from human and veterinary therapy are not eliminated completely in municipal sewage treatment plants and are therefore discharged into receiving waters(1). Wastewater treatment processes often were not designed to remove them from the effluent(2). Selected organic waste compounds may be degrading to new and more persistent compounds that may be released instead of or in addition to the parent compound(2). Studies have indicated that several polar pharmaceutically active compounds can leach through subsoils into aquifers(1)..
Independent reference data for Stavudine (CAS 220020-60-0), compiled from public chemistry databases.
| CAS Registry Number | 220020-60-0 |
|---|---|
| PubChem CID | 18283 |
| Molecular formula | C10H12N2O4 |
| IUPAC name | 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione |
| UNII (FDA) | BO9LE4QFZF |
| Molecular Weight | 224.21 |
|---|---|
| XLogP3 | -0.8 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 2 |
| Exact Mass | 224.07970687 |
| Monoisotopic Mass | 224.07970687 |
| Topological Polar Surface Area | 78.9 |
| Heavy Atom Count | 16 |
| Melting Point | 318 to 320 °F (NTP, 1992) |
|---|---|
| Melting Point | 159-160 °C |
| Melting Point | 165-166 °C |
| Melting Point | 159 - 160 °C |
| Solubility | 50 to 100 mg/mL at 70 °F (NTP, 1992) |
| Solubility | 5-10 g/100 mL at 21 °C |
| Solubility | In water, 83 mg/mL at 23 °C |
| Solubility | 4.05e+01 g/L |
| LogP | -0.72 |
| LogP | log Kow = -0.72 at 37 °C |
stavudine; 3056-17-5; sanilvudine; Zerit; 2',3'-Didehydro-3'-deoxythymidine; Estavudina; Stavudinum; Thymidine, 2',3'-didehydro-3'-deoxy-; Zerit Xr; BMY-27857; 3'-Deoxy-2'-thymidinene; 1-((2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; D 4T (nucleoside); 2',3'-Didehydro-3'-deoxythimidine; 3'-Deoxy-2',3'-didehydrothymidine; BMY 27857
| Reported hazard statements | H302 (66.7%), H315 (33.3%), H319 (33.3%), H335 (33.3%), H341 (33.3%), H361 (33.3%), H362 (33.3%), H372 (33.3%) |
|---|
H302 (66.7%): Harmful if swallowed [Warning Acute toxicity, oral]
H315 (33.3%): Causes skin irritation [Warning Skin corrosion/irritation]
Stavudine · CAS 220020-60-0 · C10H12N2O4. UNII BO9LE4QFZF. Melting Point: 318 to 320 °F (NTP, 1992); Melting Point: 159-160 °C; Melting Point: 165-166 °C.
Source: PubChem / Wikidata; the batch COA governs where values differ.
Supplier: Jinan Shenghe Chemical Co., Ltd.
中文页面: Stavudine